Skip to main content

Table 2 Frequency of Use of Anti-Diabetic Medications

From: Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression

Anti-Diabetic Medications

Diabetes (N = 55.972)

Diabetic Neuropathy (N = 2,146)

Diabetes and Depression (N = 2,379)

P-Value

 

N

%

N

%

N

%

DM v DN

DM v DD

DN v DD

Sulfonylurea

         

   Glimepiried

2,821

5.04

180

8.29

192

8.07

*

*

0.8823

   Glipizide

9,034

16.14

458

21.34

554

23.29

*

*

0.1846

   Glyburide

7,446

13.30

451

21.02

466

19.59

*

*

0.3454

   Any Sulfonylurea

18,207

32.53

924

43.06

1,072

45.06

*

*

0.3253

Meglitinide

         

   Nateglinide

222

0.40

19

0.89

6

0.25

***

0.5252

***

   Repaglinide

863

1.54

63

2.94

1

2.27

*

***

0.1790

   Any Meglitinide

1,078

1.93

82

3.32

60

2.52

*

0.1059

***

Biguanide

         

   Metformin HCL

15,744

28.13

952

44.36

1,072

45.06

*

*

0.8625

Thiazolidinedione

         

   Pioglitazone HCL

2,371

4.24

227

10.58

233

9.79

*

*

0.4238

   Rosiglitazone Maleate

3,073

5.49

287

13.37

292

12.27

*

*

0.2650

   Any Thiazolidinedione

5,283

9.44

491

22.88

494

20.77

*

*

***

Alpha Glucose Inhibitor

         

   Acarbose

256

0.46

13

0.61

18

0.76

0.5883

0.0939

0.7412

   Miglitol

112

0.20

13

0.61

1

0.04

**

0.2222

*

   Any Alpha Glucose Inhibitor

363

0.65

26

1.21

19

0.80

***

0.6553

0.2072

Insulin

         

   Insulin Glargine

272

0.49

68

3.17

75

3.15

*

*

0.9976

   Insulin Lispro

2,837

5.07

469

21.85

359

15.09

*

*

*

   Any Insulin

2,940

5.25

493

22.97

381

16.02

*

*

*

  1. *P-value ≤ 0.0001; **P-value ≤ 0.001; ***P-value ≤ 0.05.
  2. P values based on Tukey-Kramer method to adjust for multiple comparisons.
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us